Title : Dulaglutide
Text : {{Infobox drug
| IUPAC_name = <!-- amino acid sequence
HGEGTFTSDV SSYLEEQAAK EFIAWLVKGG GGGGGSGGGG SGGGGSAESK
YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSQEDP
EVQFNWYVDG VEVHNAKTKP REEQFNSTYR VVSVLTVLHQ DWLNGKEYKC
KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN QVSLTCLVKG
FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGN
VFSCSVMHEA LHNHYTQKSL SLSLG
(Disulfide bridge: 90-150; 196-254. Dimer: 55; 58)
-->
| image =
| alt =
| caption =
<!-- Clinical data -->
| tradename = Trulicity
| Drugs.com = {{Drugs.com|parent|trulicity}}
| MedlinePlus =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category=
| licence_EU = yes
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = Rx-only
| legal_status =
| routes_of_administration =Injection
<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
<!-- Identifiers -->
| CAS_number = 923950-08-7
| ATCvet =
| ATC_prefix = A10
| ATC_suffix = BJ05
| PubChem = 
| IUPHAR_ligand = 7638
| DrugBank = DB09045
| ChemSpiderID = none
| KEGG = D09889
| ChEMBL = 2108027
<!-- Chemical data -->
| C=2646 | H=4044 | N=704 | O=836 | S=18
| molecular_weight = 59669.81 g/mol
}}
<!-- Definition and medical sues -->
'''Dulaglutide''', sold under the brand name '''Trulicity''' among others,<ref name=fdaPR092014/> is a medication used for the treatment of [[type 2 diabetes]].<ref name=tibble2013/><ref name=lillyPR02014/> It can be used once weekly.

<!-- History and culture -->
It is a [[glucagon-like peptide-1 receptor agonist]] (GLP-1 agonist) consisting of GLP-1(7-37) covalently linked to an Fc fragment of human IgG4. [[glucagon-like peptide-1|GLP-1]] is a hormone that is involved in the normalization of level of glucose in blood (glycemia). The [[Food and Drug Administration|FDA]] approved dulaglutide for use in the United States in September 2014.<ref name=fdaPR092014/>

==Medical uses==
The compound is indicated for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. Dulaglutide is not indicated in the treatment of subjects with type 1 diabetes mellitus or patients with diabetic ketoacidosis because these problems are the result of the islet cells being unable to produce insulin and one of the actions of Dulaglutide is to stimulate functioning islet cell to produce more insulin. Dulaglutide can be used either stand-alone or in combination with other medicines for type 2 diabetes, in particular [[metformin]], [[sulfonylurea]]s, [[thiazolidinedione]]s, and [[insulin]] taken concomitantly with meals.<ref name="pmid25029955">{{cite journal |vauthors=Terauchi Y, Satoi Y, Takeuchi M, Imaoka T |title=Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study |journal=Endocr. J. |volume= 61|issue= 10|pages= 949–59|date=July 2014 |pmid=25029955 |doi= 10.1507/endocrj.ej14-0147}}{{primary source inline|date=May 2016}}</ref>{{primary source inline|date=May 2016}}

A [[meta-analysis]] in 2017 did not support the suggestion that treatment with GLP-1 agonists or DPP-4 inhibitors increased all-cause mortality in type 2 diabetics.<ref>{{cite journal|last1=Liu|first1=J|last2=Li|first2=L|last3=Deng|first3=K|last4=Xu|first4=C|last5=Busse|first5=JW|last6=Vandvik|first6=PO|last7=Li|first7=S|last8=Guyatt|first8=GH|last9=Sun|first9=X|title=Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.|journal=BMJ (Clinical Research Ed.)|date=8 June 2017|volume=357|pages=j2499|pmid=28596247|doi=10.1136/bmj.j2499|pmc=5463186}}</ref>

==Side effects==
The most common side effects include gastrointestinal disorders, such as [[dyspepsia]], [[decreased appetite]], [[nausea]], [[vomiting]], [[abdominal pain]], [[diarrhea]].<ref name="pmid24742660">{{cite journal |vauthors=Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z |title=Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) |journal=Diabetes Care |volume=37 |issue=8 |pages=2149–58 |date=August 2014 |pmid=24742660 |doi=10.2337/dc13-2761 |url=http://care.diabetesjournals.org/content/37/8/2149.full |accessdate=2015-03-01 |pmc=4113177}}</ref> Some patients may experience serious adverse reactions: [[acute pancreatitis]] (symptoms include persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting), [[hypoglycemia]], [[renal impairment]] (which may sometimes require hemodialysis). The risk of hypoglycemia is increased if the drug is used in combination with [[sulfonylurea]]s or [[insulin]].<ref name="pmid24918645">{{cite journal |author=Amblee A |title=Dulaglutide for the treatment of type 2 diabetes |journal=Drugs Today |volume=50 |issue=4 |pages=277–89 |date=April 2014 |pmid=24918645 |doi=10.1358/dot.2014.50.4.2132740 |url=}}</ref><ref name="pmid24485345">{{cite journal |vauthors=Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E |title=Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials |journal=Diabetes Res. Clin. Pract. |volume=103 |issue=2 |pages=269–75 |date=February 2014 |pmid=24485345 |doi=10.1016/j.diabres.2014.01.010 |url=}}</ref>

==Contraindications==
The compound is contraindicated in subjects with [[hypersensitivity]] to the [[active ingredient]] or any of the product's components.
As a precautionary measure, it was recommended in 2013 that patients with a personal or family history of [[medullary thyroid cancer]] or affected by [[multiple endocrine neoplasia]] type 2 should not take dulaglutide, because it could increase the risk of these cancers.<ref name="pmid23403741">{{cite journal |vauthors=Samson SL, Garber A |title=GLP-1R agonist therapy for diabetes: benefits and potential risks |journal=Curr Opin Endocrinol Diabetes Obes |volume=20 |issue=2 |pages=87–97 |date=April 2013 |pmid=23403741 |doi=10.1097/MED.0b013e32835edb32 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1752-296X&volume=20&issue=2&spage=87 |accessdate=2014-09-30}}</ref>

==Mechanism of action==
Dulaglutide binds to glucagon-like peptide 1 receptors, slowing gastric emptying and increases insulin secretion by pancreatic Beta cells. Simultaneously the compound reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas, which is known to be inappropriate in the diabetic patient. GLP-1 is normally secreted by [[L cell]]s of the gastrointestinal mucosa in response to a meal.<ref name="pmid24373234">{{cite book |vauthors=Nadkarni P, Chepurny OG, Holz GG |title=Regulation of glucose homeostasis by GLP-1 |journal=Prog Mol Biol Transl Sci |volume=121 |issue= |pages=23–65 |year=2014 |pmid=24373234 |pmc=4159612 |doi=10.1016/B978-0-12-800101-1.00002-8 |url=|series=Progress in Molecular Biology and Translational Science |isbn=9780128001011 }}</ref>

==References==
{{Reflist|refs=

<ref name=fdaPR092014>{{cite press release |url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm |date=Sep 18, 2014 |title=FDA approves Trulicity to treat type 2 diabetes |publisher=FDA |deadurl=no<!--added to archive.org-->}}</ref>

<ref name=lillyPR02014>{{cite press release |url= https://investor.lilly.com/releasedetail.cfm?ReleaseID=828056 |title= Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes |publisher= Eli Lilly |date= Feb 25, 2014}}</ref>

<ref name=tibble2013>{{cite journal |url= http://www.medscape.com/viewarticle/803916_4 |title= Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes: A Review of Current Literature |author1=Courtney Aavang Tibble |author2=Tricia Santos Cavaiola |author3=Robert R Henry |journal= Expert Rev Endocrinol Metab |date= 2013 |volume= 8 |issue= 3 |pages= 247–259 |doi=10.1586/eem.13.20|pmid= 30780817 }}</ref>

}}

{{Oral hypoglycemics and insulin analogs|state=expanded}}
{{Signaling peptide/protein receptor modulators}}

[[Category:Glucagon-like peptide-1 receptor agonists]]
[[Category:Eli Lilly and Company]]
